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I. Overview
DLC-1 was originally identified as a potential tumor suppressor. One of the key biochemical
functions of DLC-1 is to serve as a GTPase activating protein (GAP) for members of the Rho
family of GTPases, particularly Rho A-C and CDC 42. Since these GTPases are critically
involved in regulation of the cytoskeleton and cell migration, it seems clear that DLC-1 will
also influence these processes. In this review we examine basic aspects of the actin cyoskeleton
and how it relates to cell motility. We then delineate the characteristics of DLC-1 and other
members of its family, and describe how they may have multiple effects on the regulation of
cell polarity, actin organization, and cell migration.
II. Basic Aspects of Cytoskeletal Function in Cell Migration and Tumor Cell
Invasion
Cell Migration and Tumor Invasion
The invasive and metastatic characteristics of cancer cells are dependent on their ability to
migrate effectively through the tumor microenvironment. Thus alteration in migratory ability
is one of the hallmarks of the epithelial-mesenchymal transition that is so pivotal to tumor
progression [1]. Cell migration is an extraordinarily complex process involving many different
structural proteins and signaling pathways [2], and it is manifested differently in various cell
types and under differing environmental conditions. The classic model of cell migration
pertains to fibroblast-type cells migrating on a two-dimensional surface and is typified by cell
polarization with an extensive leading lamellipodium and a narrow retracting tail. However,
many other morphologies of cell locomotion can occur such as the pseudopodial-type migration
associated with hematopoietic cells and the movements of epithelial sheets without loss of cell-
cell contact [3]. Further, it is becoming increasing clear that cells migrate very differently in a
three-dimensional tissue or culture environment than they do in two-dimensional situations.
Cell motility is intimately linked to the functions of the actinomyosin cytoskeleton and involves
iterative and cyclical regulation of key aspects of cytoskeletal function [4,5] Rho family small
GTPases are key regulators of signaling pathways that regulate actin organization and cell
migration [6,7]. In the sections below we will describe some of the major pathways that control
cell polarity and the functions of the actin-myosin contractile apparatus. In particular, we focus
on the function of DLC-1, a negative regulator of Rho GTPase function [8]. We discuss how
the loss of DLC-1 may lead to aberrant Rho GTPase function and contribute to the aberrant
migration, invasion and metastatic properties of cancer cells.
Cell Matrix Interaction and Cell Motility
In order for cells to move they must grip and pull against the extracellular matrix (ECM).
Although other proteins and glycosaminoglycans also play a part, it is the integrin family of
heterodimeric transmembrane proteins that plays the primary role in mechanically linking
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between the multiple proteins of the ECM and the actin cytoskeleton [9]. Various integrins
have extracellular domains with affinities for different ECM proteins such as fibronectin,
laminin or collagen, while the intracellular tails of integrins can link directly to specialized
cytoskeletal proteins including talin, filamin and paxillin that then directly or indirectly bind
actin, thus providing a bridge between the exterior and interior of the cell. The specialized
organelles of integrin-mediated cell-matrix adhesions are called focal contacts or focal
adhesions and are complex, dynamic multiprotein structures [10,11]. Although integrins are
key structural molecules it is important to realize that they also are vitally important in a number
of signal transduction processes. Thus our laboratory and others have extensively explored the
impact of integrins on the ERK mitogen-activated protein kinase pathway, as well as on other
key signaling processes that impact on cell proliferation or differentiation [12,13]. It is also
clear that integrin signaling plays a major role in the regulation of directional cell migration
[14].
Role of Rho Family Proteins in Cytoskeletal Regulation
Starting with the seminal observations of Hall and colleagues in the early 1990s [15], it has
become manifest that Rho family GTPases are critically involved in extracellular signal-
stimulated regulation of the cytoskeleton and cell motility. The family is comprised of 20
mammalian members, with RhoA, Rac1 and Cdc42 the most studied and best characterized
[16]. Rho GTPases function as GDP/GTP-regulated binary switches (Fig. 1). Activated cell
surface receptors and integrins stimulate guanine nucleotide exchange factors (RhoGEFs) to
promote formation of the active GTP-bound protein, which then engages downstream effectors.
GTPase activating proteins (RhoGAPs) stimulate GTP hydrolysis, returning the GTPase to the
inactive GDP-bound state. Less is known regarding how RhoGAPs may be regulated by
extracellular signals.
Rho GTPases regulate distinct actin reorganization processes. A very simplistic summary
would indicate that active RhoA promotes actin filament bundling (stress fibers) and focal
adhesion formation, active Rac1 promotes actin accumulation at the leading edge of migrating
cells and the extension of the lamellipodium, and active Cdc42 controls cell polarity and
extension of actin microspikes and filopodia. Obviously the true situation is much more
complex [17] but the simple picture will be helpful to keep in mind in the more detailed
discussion below. An exciting new aspect of Rho and other small GTPases is the visualization
of the active states of these GTPases in living cells, clearly demonstrating that extracellular
stimuli cause a precise spatio-temporal activation of the GTPase that is intimately associated
with the formation of actin structures and the directionality of migration [18,19].
Basic aspects of actinomyosin network organization
The lamellipodium, a key structure underlying cell motility, is supported by a highly branched
actin network. Lateral branching of actin is mediated by the binding of the multi-protein Arp2,3
complex to an existing actin filament and is regulated by a set of proteins that includes Wave/
Scar, Abi,Nap125, Sra-1 and HSPC-300 that in turn is regulated by the Rac GTPase;
alternatively the Arp2,3 complex can be regulated by WASP or N-WASP which are activated
via Cdc42 [20,21]. Another key aspect of lamellipodial function, essential to cell migration,
concerns the actin severing activity of cofilin and related proteins. Cofilin's severing ability is
inactivated by phosphorylation at the serine 3 position, a process controlled by the action of
kinases, including LIM kinase and TES kinases, and of phosphatases, particularly of the
slingshot and chronophin families [22,23]. Regulation of this phosphorylation process can in
part be traced back to Rho family GTPases; for example Rac or Cdc42-mediated activation of
PAK kinases leads to phosphorylation and activation of LIM kinase thus increasing cofilin
activity [24]. An interesting recent finding is the role of the coronin 1b protein as a coordinator
of the activities of cofilin and the Arp2/3 complex in lamellipodial regulation [25]. The VASP/
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Ena proteins represent another important set of modulators of lamellipodial function. These
proteins inhibit capping of actin filament barbed ends and also decrease the density of Arp2/3
mediated branching; this serves to regulate the overall geometry of the lamellipodium [26].
The VASP/Ena proteins are regulated in part via phosphorylation by cyclic AMP and cyclic
GMP activated kinases.
Contractility is a key aspect of cell shape and migration. Rho A contributes to contractility
through its ability to trigger increased phosphorylation of the light chain of myosin II. Rho
activates Rho kinases (ROCK I and II) which can both directly phosphorylate myosin light
chain and also phosphorylate and inhibit myosin light chain phosphatase, both events leading
to increased myosin light chain phosphorylation, increased actinomyosin contractility, and the
enhanced formation of stress fibers [17,27,28]. In addition Rho also contributes to stress fiber
formation by activating the formin protein mDia1 that, in cooperation with profilin, promotes
barbed-end growth of long actin filaments [29].
Regulation of Polarity and Directionality
Migrating cells assume a polarized form with a leading lamellipodium and a retracting tail.
This polarity is essential for maintaining directional rather than random cell migration. Rac,
and especially Cdc42, play essential roles in initiating and maintaining cell polarity, acting
through several different mechanisms. One important aspect involves the formation of a
complex between PAK kinase, the Rac-specific GEF PIX, the Arf small GTPase-specific GAP
Git1 and the focal adhesion protein paxillin that contributes to localized activation of Rac near
the leading edge; in contrast, formation of a complex of comprised only of paxillin and Git1
in the tail leads to Rac inactivation [30,31]. Another key aspect of cell polarity involves Cdc42
regulation of the Par3/Par6/atypical PKC complex that is involved in microtubule function and
leads to orientation of the microtubule organizing center in the direction of the leading edge
[32]. As mentioned above Cdc42 also contributes to formation of highly polarized filopodia,
acting in part via the formin mDia2 to promote extension at the barbed end of the actin filament
[3]. Some of the roles of Rho GTPases in regulation of cell polarity and actin organization (and
thus possible sites of DLC-1 actions) are highlighted in Fig 2.
Endo/Exocytosis and Cell Migration
It has long been thought that vesicle trafficking processes contribute to cell motility, for
example by bringing adhesion receptors to the leading edge of the cell [4]. However, recent
studies have unveiled complex interactions between the Rho, Arf and Rab families of small
G-proteins that link vesicular trafficking to cell migration via multiple pathways. The Arf
proteins promote vesicle formation by assisting in the assembly of coat-protein complexes
[33]. In particular, Arf6 operates in the cell periphery and endosomes where it can recruit and
activate phosphatidylinositol kinases. There is also a complicated relationship between Arf6
activation and Rac activation; this may be mediated in part through the Dock180-Elmo complex
which is a Rac-specific GEF. In addition, Rac associated with lipid rafts can shuttle between
the plasma membrane and internal depots in an anchorage dependent fashion; in this context
Arf 6 is involved in the return of lipid rafts to the plasma membrane [34]. Other recent studies
have found a link between the Rab family of small GTPases that regulate many aspects of
membrane trafficking and the process of Rac activation. Thus Rab5 has been implicated in a
key functional recycling of Rac that involves co-recruitment of Rac and the Rac-specific GEF
Tiam1 to endosomal surfaces, followed by shuttling of Rac to the plasma membrane where it
triggers actin meshwork formation [35]. These recent examples probably herald the emergence
a rich new vein of information.
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III RhoGAPs and their Role in Control of the Cytoskeleton and cell migration
Basic aspects of RhoGAPs
As discussed earlier, Rho GTPase GDP/GTP cycling is controlled by two classes of regulatory
proteins that accelerate the otherwise very slow intrinsic guanine nucleotide exchange and GTP
hydrolysis activity [36]. There are two major RhoGEF families, one comprised of the Dbl
family (69 members) and the other the DOCK family (11 members) [37]. Similarly, the number
of RhoGAPs (>70) also greatly outnumber the number of Rho GTPases [38,39]. That there
exist multiple GEFs and GAPs, as well as effectors, for a single Rho GTPase reflects the critical
role of these proteins as nodes in complex signaling networks.
Much recent evidence has uncovered a striking role for the mutation or aberrant expression of
many RhoGEFs and RhoGAPs in a multitude of cellular processes and disease states, especially
cancer and the related processes of cytoskeletal organization and cell migration [40]. For this
review, we will focus on RhoGAPs and particularly the DLC family of RhoGAPs. All
RhoGAPs share a conserved RhoGAP catalytic domain [38,39]. Otherwise, they show little
sequence similarity in their remaining sequences, which typically contain multiple additional
protein-protein and protein-lipid interacting domains, as well as many putative phosphorylation
sites. These domains dictate the specific subcellular localization and regulation of each
RhoGAP [39]. Such mechanisms of control allow high spatial and temporal control of the
termination of GTPase activation, preventing inappropriate or prolonged signals. The spatial
regulation of Rho activation in turn influences effector utilization, thus providing a critical
mechanism of regulation of Rho GTPase function. Thus, the GAPs serve a critical signaling
nodes, incorporating diverse cellular stimuli in order determine specific Rho GTPase outcomes.
In contrast to RhoGEFs, much less is known regarding RhoGAP regulation. A few RhoGAPs
have been studied in molecular detail, including p190RhoGAP and Deleted in liver cancer-1
(DLC-1). For example, p190RhoGAP is tyrosine phosphorylated and binds to the RasGAP,
p120RasGAP, both regulating its function [41]. However, very little is known about the full
cellular regulation mechanisms of most of the RhoGAPs. This will be a great but important
challenge in the Rho GTPase field, as different RhoGAPs likely play different and specific
roles in different aspects of Rho GTPase function. Uncovering the signaling mechanisms that
regulate RhoGAPs in specific cellular contexts will be necessary for a full understanding of
Rho GTPase function. The future challenges will especially include an understanding of 1)
which Rho GTPases are the targets of each RhoGAP in vivo, 2) which downstream signaling
targets of each Rho GTPase do the GAPs affect, 3) which RhoGAPs are redundant and which
are specific to certain Rho functions and 4) which Rho GTPases are most involved in disease
processes and could serve as drug targets to specifically affect certain aspects of GTPase
function without altering others. Below we discuss what is known regarding DLC-1 and related
RhoGAPs.
DLC-1 in Cell Migration and Invasion
First identified as a gene deleted in liver cancer, subsequent studies found loss of DLC-1 gene
expression in a wide variety of human cancers, including lung and breast [8]. Interestingly, the
rate of heterozygous loss of DLC-1 in some cancer types approaches that of p53, underscoring
its potential role as a tumor suppressor [42]. Additionally, recent genome-wide sequencing
analyses of human tumors have identified missense mutations in DLC-1 [43,44]. Likewise,
several studies have demonstrated that reintroduction of DLC-1 into liver, lung or breast cancer
cell lines results in decrease tumorigenic growth [45-47], and in a recent mouse model of liver
cancer, loss of DLC-1 together with Myc oncogene activation resulted in increased tumor
growth [42]. Together, these results demonstrate an important role for DLC-1 in cancer and
support a tumor suppressor role for DLC-1. DLC-2 and DLC-3 are highly related isoforms of
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DLC-1 and similar less extensive observations also support their role as tumor suppressors
[8]. Whether loss of DLC-2 and DLC-3 as well as that of DLC-1 must occur in cancer will be
a subject of future investigation.
All RhoGAPs contain an ∼150 amino acid RhoGAP catalytic domain [38,39]. DLC-1 and
related isoforms contain two additional domains, an N-terminal SAM domain and a C-terminal
START domain (Fig. 3). In vitro, we determined that the isolated RhoGAP domain acts as a
potent GAP for RhoA, RhoB, RhoC, and to a lesser degree for Cdc42, but not Rac1 [48]. SAM
domains (∼70 amino acids) are putative protein interaction modules found in a diverse
spectrum of signaling and nuclear proteins, typically as components of multi-domain proteins
(e.g., Eph-related tyrosine kinases, Ets transcription factors). SAM domains have been shown
to homo- and hetero-oligomerize, and can additionally bind both non-SAM domain-containing
proteins. Structural studies of the SAM domain of DLC-2 suggest that it may bind lipids
(although the specificity and in vivo relevance is unknown [49]). START domains (∼120 amino
acids) are lipid-binding domains found in proteins that transfer lipids between organelles.
START domains are found in StAR, HD-ZIP and other signaling proteins. Representatives of
the START domain family have been shown to bind different ligands such as sterols (StAR
protein) and phosphatidylcholine.
Much less is known about the function of the SAM and START domains in DLC function.
Our studies have found that the SAM domain appears to be involved in autoinhibition of the
RhoGAP activity [50]. Between the SAM and RhoGAP domains is a long unstructured region
that includes a phosphorylation-independent binding site (Y442 in human DLC-1) for the Src
homology 2 domains of tensin family of adaptor proteins [51,52]. This binding region is
necessary for focal adhesion localization as well as tumor suppression, suggesting that
RhoGAP activity at or near focal adhesions and not total cell RhoGAP activity is necessary
for tumor suppression. A phosphorylation site for rat DLC-1 has also been identified in this
N-terminal region (S329), by activated AKT and RSK1 kinases, although the functional
consequence of this modification has not been determined (Fig 3). Future work will involve
understanding how DLC-1 is regulated by its additional domains and phosphorylation, as well
as the precise the downstream mechanisms through which DLC-1 acts as a tumor suppressor.
Since aberrant activation of RhoA and RhoC has been implicated in oncogenesis, a logical
hypothesis is that loss of DLC-1 function will lead to hyperactivation of these Rho GTPases,
resulting in their stimulation of cell proliferation. Consistent with this possibility, two studies
suggest that tumor suppression by DLC-1 works through RhoA [53,54], although our study
demonstrated partial RhoGAP independent tumor suppression by DLC-1 [48]. Our studies also
found that ectopic expression of DLC-1 in DLC-1 deficient lung tumor cells reduced the level
of activated RhoA. Additionally, although FA association does not appear to alter DLC-1
RhoGAP activity in vivo or in vitro (unpublished results), FA association appears to be required
for proper spatial regulation of Rho GTPases for tumor suppression.
As indicated above the Rho and Cdc42 GTPases play multiple critical roles in the regulation
of actin organization, cell polarity, and cell migration. Thus the aberrant function of DLC-1
seen in many types of cancers would be expected to influence the activation state of these
critical GTPases and to have significant effects on cytoskeletal organization and cell motility.
We have recently explored this aspect in some detail [50]. Thus, overexpression of various
activated forms of DLC-1 leads to profound changes in cytoskeletal organization with
disruption of focal adhesions and the rapid, continuing and apparently random extension of
long protrusions, as well as inability to retract the tail of the cell. These effects are likely
mediated via reduction in Rho activity. Using single cell tracking assays, we have also found
that overexpression of a form of DLC-1 (DLC-1ΔSAM) that lacks the SAM domain (and is
thus activated), but which retains the remainder of the N-terminal region, has a profound effect
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on cell motility. DLC-1ΔSAM increases the velocity of migration but reduces directionality;
the overall result in bulk migration assays is a reduction in migration, presumably due to loss
of directionality, an effect that may be mediated via DLC-1's inhibition of CDC42 and
consequent effects on polarity. These effects on migration are not seen with active forms of
DLC-1 that lack the N-terminal region. DLC-1ΔSAM is capable of associating with focal
adhesions, but when it is expressed extensive disruption of these structures occurs. Thus it is
not clear whether the profound effects of DLC-1ΔSAM on migration are due to its ability to
localize to residual focal adhesions, or due to other interactions mediated through the N-termus.
Further evidence for a key role for focal adhesion localized DLC-1 comes from our studies of
a truncated version of the protein (DLC-1N) that contains the N-terminal domain but not the
GAP domain; we also constructed a second version with a mutation at the Y442 site (DLC-1N
Y442A). DLC-1N retains the ability to localize to focal adhesions, but the version with the
mutation at 442 does not. Overexpression of DLC-1N leads to almost complete paralysis of
cell movement, whereas the 442 mutant had no effect. Using fluorescence microscopy and
immunochemistry we have demonstrated that DLC-1N displaces endogenous DLC-1 from
focal adhesions. This strongly argues that, not only GAP activity, but also proper focal adhesion
localization of DLC-1, play important roles in the control cell migration. Presumably focal
adhesion associated DLC-1 can orchestrate localized effects on Rho and CDC42 that are critical
for control of cell velocity and directionality.
In addition to the work described above, a number of other studies have demonstrated that
DLC-1 inhibits cell motility or invasiveness in cultures of liver, breast, ovarian and lung cancer
cell lines [48,55–58]. Further, the observed effects of DLC-1 on cell motility are consistent
with its proposed role as a metastasis suppressor gene [8]. For example, using gene chip array
analysis several groups have found that DLC-1 is unde-rexpressed in highly metastatic cells
[55,59].
In summary, the RhoGAP DLC-1 and related family members play important roles both in the
regulation of tumorigenesis and in associated cytoskeletal activities that impact on the motile,
invasive and metastatic characteristics of cancer cells. Whether these two aspects of DLC-1
function occur through the same or different GTPase pathways will be an important goal of
future research. The functions of DLC-1 seem to depend not only on its enzymatic activity as
a GAP but also on its focal contact localization and its interactions with other proteins that
regulate and localize its function.
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Figure 1. Rho GTPases function as GDP/GTP regulated on-off switches in signal transduction
Rho GTPases function as GDP/GTP regulated on-off switches in signal transduction. Rho
GTPase cycle between an active GTP-bound and an inactive GDP-bound state. This cycle is
regulated by RhoGEFs that promote GDP/GTP exchange and by RhoGAPs that stimulate
hydrolysis of the bound GTP. Activated Rho GTPases preferentially associate with
downstream effectors, which in turn regulate cytoplasmic signaling networks that control actin
organization and other cellular processes. Extracellular stimulus activation of cell surface
receptors cause activation of Rho GTPase primarily by activation of RhoGEFs. There is
emerging evidence that stimuli can regulate Rho GTPase by controlling the activity of
RhoGAPs.
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Figure 2. DLC-1 Affects the Cytoskeleton and Cell Motility Via Rho and CDC42
This figure illustrates key signaling pathways involving the Rho and CDC 42 GTPases that
are implicated in control of the cytoskeleton, cell polarity and cell migration. Since DLC family
proteins are GAPs for Rho and CDC42, they may influence all of these pathways.
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Figure 3. Interactions of DLC-1
Known interactions and functions of DLC-1. To date, biochemical and cellular analyses of
both rat (p122RhoGAP) and human DLC-1 demonstrate that DLC-1 is a potent GAP primarily
for RhoA and related isoforms. Additionally, there is also evidence for Cdc42 GAP activity.
Our structure-function studies found that the SAM domain may serve as an autoinhibotory
domain for the RhoGAP catalytic activity. Insulin-stimulated activation of the PI3K-AKT or
MEK-ERK-RSK1 protein kinase cascades has been shown to cause phosphorylation at S322
in rat DLC-1 (S329 in human DLC-1). Two recent studies determined that Y422 in human
DLC-1 was critical for this association; this residue is a component of a phosphorylation-
independent motif that binds the Src homology 2 (SH2) domain of tensin family proteins
(tensin-1, cten, etc.) that are associated with focal adhesions.
Kim et al. Page 12
Cancer Metastasis Rev. Author manuscript; available in PMC 2010 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
